News
Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron ...
Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...
Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...
Regeneron announced FDA accelerated approval for Lynozyfic™ to treat advanced multiple myeloma in heavily pre-treated patients. Quiver AI Summary Regeneron Pharmaceuticals announced that the FDA ...
Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...
Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus ...
--Regeneron Pharmaceuticals, Inc. today announced that the European Commission has granted conditional marketing approval of Lynozyfic™ to treat adults with relapsed and refractory multiple myeloma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results